Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Stock Has Consensus Target Price of $51.40

by · The Cerbat Gem

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG – Get Free Report) has earned a consensus rating of “Moderate Buy” from the seven analysts that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $51.40.

A number of research analysts recently issued reports on the company. Weiss Ratings downgraded Hemab Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, September 25th. Jefferies Financial Group upped their price target on Hemab Therapeutics from $39.00 to $47.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. HC Wainwright raised their price target on shares of Hemab Therapeutics from $52.00 to $60.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Finally, Wedbush lifted their price objective on shares of Hemab Therapeutics from $55.00 to $64.00 and gave the company an “outperform” rating in a report on Wednesday, August 12th.

Get Our Latest Analysis on Hemab Therapeutics

Hedge Funds Weigh In On Hemab Therapeutics

A number of large investors have recently modified their holdings of the business. Citadel Advisors LLC bought a new stake in Hemab Therapeutics during the second quarter worth $19,226,000. Braidwell LP bought a new position in shares of Hemab Therapeutics in the 2nd quarter valued at about $5,877,000. State Street Corp acquired a new position in shares of Hemab Therapeutics during the 2nd quarter worth about $2,825,000. Opaleye Management Inc. acquired a new position in shares of Hemab Therapeutics during the 2nd quarter worth about $1,750,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Hemab Therapeutics in the 2nd quarter valued at about $688,000.

Hemab Therapeutics Stock Performance

Shares of COAG opened at $30.59 on Thursday. The company has a market capitalization of $1.43 billion and a price-to-earnings ratio of -1.23. Hemab Therapeutics has a twelve month low of $23.00 and a twelve month high of $55.42. The firm has a 50 day moving average of $44.04.

Hemab Therapeutics (NASDAQ:COAG – Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.17). As a group, research analysts forecast that Hemab Therapeutics will post -3.09 EPS for the current year.

About Hemab Therapeutics

(Get Free Report)

Hemab Therapeutics (NASDAQ: COAG) is a clinical-stage biopharmaceutical company developing treatments for serious and potentially life-threatening bleeding disorders. The company focuses on rare conditions for which existing therapies may be limited, inconvenient, or ineffective for some patients.

Hemab’s lead investigational program, HMB-001, is an engineered bispecific antibody designed to improve blood clotting by enhancing thrombin generation through inhibition of tissue factor pathway inhibitor.

Featured Stories